Lexapro Shows Modest Sales Gains With Close Of 2004, Forest Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the antidepressant grew 3% sequentially in the quarter ended Dec. 31, but the gains were more than offset by a 50% decline in Celexa due to generic competition. Forest's better-than-expected quarterly earnings performance partially reflects a one-time, $30 mil. sale of the flu therapy Flumadine to the U.S. government.